30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

2014 Revenue: Anika Therapeutics

4Q14 revenue: $13.2MM, -14%

2014 revenue: $61.9MM, +11% (MONOVISC +258%)


  • 4Q revenues impacted by lack of unique CMS J-Code for MONOVISC for 8 months post-launch, DePuy Mitek inventory reset, temporary slowdown in ex-U.S. sales
  • Seeks to reach 15% share of global viscosupplementation market by end of 2018 (gained close to 2% share in U.S. even without unique J-Code; expects to more than double that by end of 2015)
  • Overall 2014 U.S. market share for ORTHOVISC and MONOVISC at 21%
  • DePuy Mitek targeted competitive conversion, and thus saw minimal cannibalization of ORTHOVISC sales
  • Adding and maintaining existing high quality ex-U.S. distribution partners taking longer than expected; making strides in Asia and moving forward with MONOVISC product registrations in Latin America
  • Completed biostatistics analysis of multi-national Cingal clinical trial in 4Q and submitted CE Mark application; filed PMA submission in early 2/15 (ahead of schedule)
  • 4th-gen injectable osteoarthritis product in early development
  • On track to start Phase III pivotal study in 2H15 for Hyalofast biodegradable 3D scaffold
  • Received CE Mark approval for Hyalospine